Scenesse (Afamelanotide Implant 16mg)

SCENESSE (afamelanotide 16mg) is a controlled-release formulation to deliver the photoprotective effects of this melanocortin. Skin pigmentation is activated immediately and the photoprotective effect lasts up to two months.

Recent Rosacea Blog Posts

Scenesse fast tracked for EPP in US

Scenesse continues to receive approvals for use in special cases, this time being given fast track designation status for the treatment of erythropoietic protoporphyria in the US. This approval comes after SCENESSE was granted general availability in Europe for treating EPP. Clinuvel Press Release FDA awards SCENESSE® Fast Track designation for treatment of EPP Clinuvel Pharmaceuticals […]

Continue Reading

SCENESSE approved for EPP in Europe

Clinuvel have announced that their treatment known as SCENESSE (yes another product insisting on all caps) has been approved as a treatment for Erythropoietic Protoporphyria (EPP) in Europe. SCENESSE has previously been granted Orphan Drug Designation in Europe, USA, Australia and Switzerland. Scenesse was approved for use in Italy in 2010. Europe approves novel Australian […]

Continue Reading

Scenesse has been tested as a treatment for acne, and the results are looking good. Before you get too excited, though, lets get all the disclaimers out of the way right up front … Clinuvel, the developers of Scenesse are not currently pursuing Scenesse as a treatment for acne The study presented was very small, […]

Continue Reading

Scenesse Starts Phase III Trials for EPP in the US

News today that Scenesse has progressed another step towards wider approval with the commencement of Phase III Trials. About 100 people with the condition Erythropoietic Protoporphyria (EPP) will be double blinded to receive the Scenesse implant or placebo. Their ability to tolerate sunlight will then be measured. The trials will take place in Alabama, California, […]

Continue Reading

Scenesse One Step Closer for Erythropoietic Protoporphyria (EPP)

News from Clinuvel that Scenesse (their implant of afamelanotide 16mg) has shown a provable positive effect on EPP sufferers in a US Phase 2 Trial. EPP is an acute intolerance to exposure to sunlight and UV. Sufferers of EPP describe the disease as crippling. As has been the case in other blinded trials, the study […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.